Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

This study has been completed.
Sponsor:
Information provided by:
PharmaMar
ClinicalTrials.gov Identifier:
NCT00884286
First received: April 17, 2009
Last updated: February 10, 2011
Last verified: February 2011

April 17, 2009
February 10, 2011
December 2004
July 2010   (final data collection date for primary outcome measure)
To assess the anti-tumour activity of Aplidin® given as a 1-hour weekly IV infusion, in patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00884286 on ClinicalTrials.gov Archive Site
To investigate the safety profile of Aplidin® in the patient population and to obtain additional pharmacokinetic information for the drug [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma

This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.

A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's Lymphoma.

Primary

• To assess the anti-tumour activity of Aplidin® given as a 1-hour weekly IV infusion, in patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy.

Secondary

  • To further investigate the safety profile of Aplidin® given as 1-hour weekly IV infusion in this patient population.
  • To obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Lymphoma
Drug: Aplidin®
Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
Other Name: plitidepsin
Experimental: Arm One
Aplidin® given as a 1-hour weekly IV infusion
Intervention: Drug: Aplidin®
Ribrag V, Caballero D, Fermé C, Zucca E, Arranz R, Briones J, Gisselbrecht C, Salles G, Gianni AM, Gomez H, Kahatt C, Corrado C, Szyldergemajn S, Extremera S, de Miguel B, Cullell-Young M, Cavalli F. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica. 2013 Mar;98(3):357-63. doi: 10.3324/haematol.2012.069757. Epub 2012 Oct 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
67
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent
  • Histologically confirmed aggressive lymphomas,
  • Patient requires treatment because NHL relapses
  • Measurable disease
  • Recovery from any non-hematological toxicity derived from previous treatments. The presence of alopecia and NCI-CTC grade < 2 symptomatic peripheral neuropathy is allowed.
  • Age > 18 years.
  • Performance status (ECOG) < 2
  • Adequate renal, hepatic, and bone marrow function (assessed < 14 days before inclusion in the study)
  • Left ventricular ejection fraction within normal limits.

Exclusion Criteria:

  • Prior therapy with Aplidin®.
  • Concomitant therapy with any anti-lymphoproliferative agent
  • Acute lymphoblastic leukemia.
  • CNS lymphoma.
  • HIV-associated lymphoma.
  • Prior gene therapy with viral vectors.
  • More than three previous lines of systemic biological agents or chemotherapies. Wash-out periods since the end of the precedent therapy less than:

    • 6 weeks for nitroso-urea or high dose chemotherapy
    • 3 weeks for other chemotherapies or biological agents
    • 4 weeks for radiation or radionuclide therapy (6 weeks in case of prior extensive external beam radiation (more than 25% of bone marrow distribution).
    • 4 weeks for major prior surgery
    • 30 days for any investigational product
    • 4 weeks for immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation.
  • Pregnant or lactating women.
  • Men and women of reproductive potential who are not using effective contraceptive methods
  • History of another neoplastic disease. Exceptions: Non-melanoma skin cancer,cCarcinoma in situ of any site,any other cancer curatively treated and no evidence of disease for at least 10 years.
  • Known cerebral or leptomeningeal involvement.
  • Other relevant diseases or adverse clinical conditions
  • Treatment with any investigational product in the 30 days period before inclusion in the study.
  • Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol
  • Limitation of the patient's ability to comply with the treatment or follow-up protocol.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France,   Italy,   Peru,   Puerto Rico,   Spain,   Switzerland
 
NCT00884286
APL-B-013-02
No
PharmaMar USA Inc
PharmaMar
Not Provided
Principal Investigator: Vincent Ribrag, MD Institut Gustave Roussy, France
PharmaMar
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP